Unicycive Therapeutics, Inc. (UNCY) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Los Altos, CA, United States. The current CEO is Shalabh K. Gupta.
UNCY has IPO date of 2021-07-12, 22 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $149.15M.
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
